Page 1460 - Williams Hematology ( PDFDrive )

1434 Part X: Malignant Myeloid Diseases Chapter 88: Acute Myelogenous Leukemia 1435

1208. Keating S, Suciu S, De Witte T, et al: The stem cell mobilizing capacity of patients with 1237. Yang DH, Lee JJ, Mun YC, et al: Predictable prognostic factor of CD56 expression in
acute myeloid leukemia in complete remission correlates with relapse risk: Results of patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allo-
the EORTC-GIMEMA AML-10 trial. Leukemia 17:60, 2003. geneic hematopoietic stem cell transplantation. Am J Hematol 82:1, 2007.
1209. Tremblay LN, Hyland RH, Schouten BD, Hanly PJ: Survival of acute myelogenous leu- 1238. Chim CS, Liang R, Tam CY, Kwong YL: Methylation of p15 and p16 genes in acute
kemia patients requiring intubation/ventilatory support. Clin Invest Med 18:19, 1995. promyelocytic leukemia: Potential diagnostic and prognostic significance. J Clin
1210. Hunter AE, Rogers SY, Roberts IAG, et al: Autonomous growth of blast cells is associ- Oncol 19:2033, 2001.
ated with reduced survival in acute myeloblastic leukemia. Blood 82:399, 1993. 1239. Das-Gupta EP, Seedhouse CH, Russell NH: Microsatellite instability occurs in defined
1211. Campos L, Rouault JP, Sabido O, et al: High expression of bcl-2 protein in acute mye- subsets of patients with acute myeloblastic leukaemia. Br J Haematol 114:307, 2001.
loid leukemia cells is associated with poor response to chemotherapy. Blood 81:3091, 1240. Lee ST, Jang JH, Min YH, et al: AC133 antigen as a prognostic factor in acute leuke-
1993. mia. Leuk Res 25:757, 2001.
1212. Sharawat SK, Bakhshi R, Vishnubhatla S, Bakhshi S: High receptor tyrosine kinase 1241. Benekle M, Xia Z, Donohue KA, et al: Constitutive activity of signal transducer and
(FLT3, KIT) transcript versus anti-apoptotic (BCL2) transcript ratio independently activator of transcription 3 protein in acute myeloid leukemia blasts is associated with
predicts inferior outcome in pediatric acute myeloid leukemia. Blood Cells Mol Dis short disease-free survival. Blood 99:252, 2002.
54:56, 2015. 1242. Baldus CD, Tanner SM, Ruppert AS, et al: BAALC expression predicts clinical out-
1213. Kaufmann SH, Karp JE, Svingen PA, et al: Elevated expression of the apoptotic regu- come of de novo acute myeloid leukemia patients with normal cytogenetics. Blood
lator Mcl-1 at the time of leukemic relapse. Blood 91:991, 1998. 102:1613, 2003.
1214. Zhang W, Xu HJ, Kornblau SM, et al: Growth-factor stimulation reveals two mech- 1243. Smith MA, Luxton RW, Pallister CJ, Smith JG: A novel predictive model of outcome
anisms of retinoblastoma gene inactivation in human myelogenous leukemia cells. in de novo AML based on S-phase activity and proliferative response of blast cells to
Leuk Lymphoma 16:191, 1995. haemopoietic growth factors. Leuk Res 26:345, 2002.
1215. Zhang W, Kornblau SM, Kobayashi T, et al: High levels of constitutive WAFl/Cipl 1244. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, et al:
protein are associated with chemoresistance in acute myelogenous leukemia. Clin High EVI1 expression predicts poor survival in acute myeloid leukemia: A study of
Cancer Res 1:1051, 1995. 319 de novo AML patients. Blood 101:837, 2003.
1216. Raspadori D, Lauria F, Ventura MA, et al: Incidence and prognostic relevance of CD34 1245. Lugthart S, van Drunen E, van Norden Y, et al: High EVI1 levels predict adverse out-
expression in acute myeloblastic leukemia: Analysis of 141 cases. Leuk Res 21:603, 1997. come in acute myeloid leukemia: Prevalence of EVI1 overexpression and chromo-
1217. Dalal Bi, Wu V, Barnett MJ, et al: Induction failure in de novo acute myelogenous some 3q26 abnormalities underestimated. Blood 111:4329, 2008.
leukemia is associated with expression of high levels of CD34 antigen by the leukemic 1246. Konoplev S, Rassidakis GZ, Estey E, et al: Overexpression of CXCR4 predicts adverse
blasts. Leuk Lymphoma 26:299, 1997. overall and event-free survival in patients with unmutated FLT3 acute myeloid leuke-
1218. Lee JJ, Cho D, Chung IJ, et al: CD34 expression is associated with poor clinical out- mia with normal karyotype. Cancer 109:1152, 2007.
come in patients with acute promyelocytic leukemia. Am J Hematol 73:149, 2003. 1247. Shih TT, Hou HA, Liu CY, et al: Bone marrow angiogenesis magnetic resonance imag-
1219. Shimamoto T, Ohyashiki K, Ohyashiki JH, et al: The expression pattern of erythro- ing in patients with acute myeloid leukemia: Peak enhancement ratio is an indepen-
cyte/megakaryocyte-related transcription factors GATA-1 and the stem cell leukemia dent predictor for overall survival. Blood 113:3161, 2009.
gene correlates with hematopoietic differentiation and is associated with outcome of 1248. Pérez-García A, Brunet S, Berlanga JJ, et al: CTLA-4 genotype and relapse incidence
acute myeloid leukemia. Blood 86:3173, 1995. in patients with acute myeloid leukemia in first complete remission after induction
1220. Baer MR, Stewart CC, Lawrence D, et al: Expression of the neural cell adhesion mol- chemotherapy. Leukemia 23:486, 2009.
ecule CD56 is associated with short remission duration and survival in acute myeloid 1249. Marcucci G, Maharry KS, Metzeler KH, et al: Clinical role of microRNAs in cytoge-
leukemia with t(8;21)(q22;q22). Blood 90:1643, 1997. netically normal acute myeloid leukemia: MiR-155 upregulation independently iden-
1221. Extermann M, Bacchi M, Monai N, et al: Relationship between cleaved L-selectin tifies high-risk patients. J Clin Oncol 31:2086, 2013.
levels and the outcome of acute myeloid leukemia. Blood 92:3115, 1998. 1250. Metzeler KH, Dufour A, Benthaus T, et al: ERG expression is an independent prog-
1222. Raza A, Preisler HD, Li YQ, et al: Biologic characteristics of newly diagnosed poor nostic factor and allows refined risk stratification in cytogenetically normal acute
prognosis acute myelogenous leukemia. Am J Hematol 42:359, 1993. myeloid leukemia: A comprehensive analysis of Erg, MN1, and BAALC transcript lev-
1223. Wetzler M, Baer MR, Bernstein SH, et al: Expression of c-mpl MRNA, the receptor for els using oligonucleotide microarrays. J Clin Oncol 27:5031, 2009.
thrombopoietin, in acute myeloid leukemia blasts identifies a group of patients with 1251. Groschel S, Schlenk RF, Engelmann J, et al: Deregulated expression of EVI1 defines a
poor response to intensive chemotherapy. J Clin Oncol 15:2262, 1997. poor prognostic subset of MLL-rearranged acute myeloid leukemias: A study of the
1224. Small D: Targeting FLT3 for the treatment of leukemia. Semin Hematol 45(3 Suppl 2): German-Austrian acute myeloid leukemia study group and the Dutch-Belgian-Swiss
S17, 2008. HOVON/SAKK cooperative group. J Clin Oncol 31:95, 2012.
1225. Libura M, Asnafi V, Delabesse E, et al: FLT3 and MLL intragenic abnormalities in 1252. Bochtler T, Stolzel F, Heilig CE, et al: Clonal heterogeneity as detected by metaphase
AML reflect a common category of genotoxic stress. Blood 1902:2198, 2003. karyotyping is an indicator of poor prognosis in acute myeloid leukemia. J Clin Oncol
1226. Kim DH, Lee NY, Lee MH, et al: Vascular endothelial growth factor (VEGF) gene 31:2898, 2013.
(VEGFA) polymorphism can predict the prognosis in acute myeloid leukaemia 1253. Kornblau SM, Qui YH, Zhang N, et al: Abnormal expression of FLI1 protein is an
patients. Br J Haematol 140:71, 2008. adverse prognostic factor in acute myeloid leukemia. Blood 118:5604, 2011.
1227. Tsimberidou AM, Kantarjian HM, Wen S, et al: The prognostic significance of serum 1254. Rushworth SA, Zaitseva L, Murray MY, et al: The high Nrf2 expression in human
beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predict- acute myeloid leukemia is driven by NF-κB and underlies its chemoresistance. Blood
ing survival: Analysis of 1,180 patients. Clin Cancer Res 14:721, 2008. 120:5188, 2012.
1228. Heuser M, Beutel G, Krauter J, et al: High meningioma 1 (MN1) expression as a pre- 1255. Hole PS, Darley RL, Tonks A: Do reactive oxygen species play a role in myeloid leuke-
dictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood mias? Blood 117:5816, 2011.
108:3898, 2006. 1256. Barreyro L, Will B, Bartholdy B, et al: Overexpression of IL-1 receptor accessory
1229. Gaidzik VI, Schlenk RF, Moschny S, et al: Prognostic impact of WT1 mutations in protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood
cytogenetically normal acute myeloid leukemia (AML): A study of the German- 120:1290, 2012.
Austrian AML Study Group (AMLSG). Blood 113:4505, 2009. 1257. Carter BZ, Qiu Y, Huang X, et al: Survivin is highly expressed in CD34(+)38(–) leukemic
1230. Virappane P, Gale R, Hills R, et al: Mutation of the Wilms’ tumor 1 gene is poor prog- stem/progenitor cells and predicts poor clinical outcomes in AML. Blood 120:173, 2012.
nostic factor associated with chemotherapy resistance in normal karyotype acute 1258. Chamuleau ME, Ossenkoppele GJ, van Rhenen A, et al: High TRAIL-R3 expression
myeloid leukemia: The United Kingdom Medical Research Council Adult Leukemia on leukemic blasts is associated with poor outcome and induces apoptosis-resistance
Working Party. J Clin Oncol 26:5429, 2008. which can be overcome by targeting TRAIL-R2. Leuk Res 35:741, 2011.
1231. Paschka P, Marcucci G, Ruppert AS, et al: Wilms’ tumor 1 gene mutations indepen- 1259. Byrd JC, Mrozek K, Dodge RK, et al: Pretreatment cytogenetic abnormalities are
dently predict poor outcome in adults with cytogenetically normal acute myeloid leu- predictive of induction success, cumulative incidence of relapse, and overall survival
kemia: A cancer and leukemia group B study. J Clin Oncol 26:4595, 2008. in adult patients with de novo acute myeloid leukemia: Results from Cancer and
1232. Testa U, Riccioni R, Militi S, et al: Elevated expression of IL-3Ralpha in acute myelog- Leukemia Group B (CALGB 8461). Blood 100:4325, 2002.
enous leukemia is associated with enhanced blast proliferation, increased cellularity, 1260. Bradstock K, Matthews J, Benson E, et al: Prognostic value of immunophenotyping in
and poor prognosis. Blood 100:2980, 2002. acute myeloid leukemia. Australian Leukaemia Study Group. Blood 84:1220, 1994.
1233. Schnittger S, Kinkelin U, Schoch C, et al: Screening for MLL tandem duplication in 1261. Gaiger A, Schmid D, Heinze G, et al: Detection of the WT1 transcript by RT-PCR in
387 unselected patients with AML identify a prognostically unfavorable subset of complete remission has no prognostic relevance in de novo acute myeloid leukemia.
AML. Leukemia 14:796, 2000. Leukemia 12:1886, 1998.
1234. Schoch C, Schnittger S, Klaus M, et al: AML with 11q23/MLL abnormalities as 1262. Shih LY, Kuo MC, Liang DC, et al: Internal tandem duplication and Asp835 muta-
defined by the WHO classification: Incidence, partner chromosomes, FAB subtype, tions of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia.
age distribution, and prognostic impact in an unselected series of 1897 cytogenetically Cancer 98:1206, 2003.
analyzed AML cases. Blood 102:2395, 2003. 1263. Svingen PA, Karp JE, Krajewski S, et al: Evaluation of Apaf-1 and procaspases-2, -3, -7,
1235. Di Bono E, Sartori R, Zambello R, et al: Prognostic significance of CD56 antigen -8, and -9 as potential prognostic markers in acute leukemia. Blood 96:3922, 2000.
expression in acute myeloid leukemia. Haematologica 87:250, 2002. 1264. Heckman KD, Weiner GJ, Burns CP: Persistent thrombocytopenia during remission
1236. Kahl C, Florschutz A, Jentsch-Ullrich K, et al: Primary intracranial manifestation of in acute leukemia does not preclude long-term disease-free survival. Am J Hematol
CD7/CD56-positive acute myelogenous leukemia. Onkologie 23:580, 2000. 71:236, 2002.

Kaushansky_chapter 88_p1373-1436.indd 1435 9/21/15 11:02 AM